Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Esophageal Squamous Cell Carcinoma 23Carcinoma, Hepatocellular 23Stomach Neoplasms 14Colorectal Neoplasms 13Liver Neoplasms 7Esophageal Neoplasms 6Rectal Neoplasms 5Pancreatic Neoplasms 4Cholangiocarcinoma 4Locally Advanced Rectal Cancer 3Biliary Tract Neoplasms 3Advanced Pancreatic Cancer 3Turcot syndrome 2Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Microsatellite Stable Metastatic Colorectal Cancer 2Klatskin Tumor 2Gallbladder Neoplasms 2Early Low Rectal Cancer 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of the Stomach 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Carcinoma of Esophagus 1Sarcoma 1Radiotherapy 1Pathologic Complete Response 1Pancreatic Cancer Metastatic 1

Interventions

Gemcitabine 95Cisplatin 72Capecitabine 39Oxaliplatin 38durvalumab 29Fluorouracil 27pembrolizumab 26Leucovorin 23S 1 (combination) 19Nivolumab 14Irinotecan 14lenvatinib 13Bevacizumab 13tremelimumab 10130-nm albumin-bound paclitaxel 9apatinib 8Trastuzumab 7Injections 7Immune Checkpoint Inhibitors 7Docetaxel 7Albumin-Bound Paclitaxel 7Paclitaxel 6Drug Therapy 6titanium silicide 5surufatinib 5irinotecan sucrosofate 5gemcitabine-oxaliplatin regimen 5envafolimab 5camrelizumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × toripalimab × Gastrointestinal × Clear all
NCT07619235 2026-06-01

A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer

Huazhong University of Science and Technology

Phase 4 Not yet recruiting
32 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
65 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04010071 2023-03-29

Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors

Peking Union Medical College Hospital

Phase 2 Unknown
60 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡